Clinical Trial
4 articles
Novel Kidney Drug INM004 Enters Final Trial for Life-Threatening HUS
Argentine biotech Inmunova has initiated a Phase 3 clinical trial for INM004, a novel drug designed to neutralize the Shiga toxin responsible for Haemolytic Uraemic Syndrome (HUS). This investigational therapy aims to be the first specific treatment for the severe kidney disorder, potentially preventing irreversible organ damage.
Pfizer lung cancer drug: 60% progression-free after five years
After five years, 60% of patients with a specific type of lung cancer treated with Pfizer's lorlatinib were still alive without their disease progressing, a dramatic finding compared to just 8% on the
Revolution Medicines' Experimental Pancreatic Cancer Drug Shows Promise
Revolution Medicines' experimental drug daraxonrasib doubled the median overall survival for patients with metastatic pancreatic cancer to 13.2 months in its pivotal Phase 3 trial.
Stem cell heart patch increases heart wall thickness in patients
In a small clinical trial, patients with advanced heart failure who received a stem cell-based heart patch saw their heart wall thickness increase by 4.